USPTO 2015–2025 USPTO PatentsView US Corporation

Intra-cellular Therapies, Inc.

USPTO PatentsView assignee record - 152 granted patents across 15 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

152

Total patents granted

CPC technology areas

19.1

Avg claims per patent

+34%

5-year filing velocity

The verdict

Intra-cellular holds 152 US patents across 15 technology areas, rank #2,558 of 50,000 tracked assignees.

#2,558
of 50,000 US assignees by volume: Top 17%
by Innovation Score (48.4/100): 19.1
avg claims per patent: +34%
filing velocity, last 5 yrs

Portfolio overview

Intra-cellular Therapies, Inc. has been granted 152 US utility patents between 2015 and 2025, placing Intra-cellular Therapies, Inc. at rank #2,558 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Intra-cellular Therapies, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Intra-cellular sits between Bombardier Transportation Gmbh (152 patents, rank #2,554) and Merlin Technology Inc. (152 patents, rank #2,562) - the closest US assignees by grant volume. The composite Innovation Score of 48.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 87 grants, compared with 65 in the 2015–2019 window, a +34% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Intra-cellular Therapies, Inc.'s 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Intra-cellular Therapies, Inc. against peers pursuing similar technology classes.

Bombardier Transp…

152
Fudan University

152
Guardian Industri…

152
Hideep

152
Joyson Safety Sys…

152
Mitsui Kinzoku ACT

152
Mannkind

152
Merlin Technology

152
Intra-cellular Th… ◀

152

What this shows Intra-cellular holds 152 patents at rank #2,558, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Intra-cellular

By rank, the assignees closest to #2,558 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Intra-cellular's primary technology class.

Intra-cellular's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Intra-cellular Therapies, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	11	7.2%
2016	13	8.6%
2017	17	11.2%
2018	12	7.9%
2019	12	7.9%
2020	13	8.6%
2021	16	10.5%
2022	11	7.2%
2023	12	7.9%
2024	13	8.6%
2025	22	14.5%

Which technologies does Intra-cellular Therapies, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 128

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 122

C07D - HETEROCYCLIC COMPOUNDS 107

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 18

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 6

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 5

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS 3

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 3

C07K - PEPTIDES 2

C07J - STEROIDS 1

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 1

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 1

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 1

B32B - LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM 1

B82Y - SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES 1

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#2,558

Across all tracked assignees

Innovation Score

48.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Intra-cellular Therapies, Inc. hold?

Intra-cellular Therapies, Inc. holds 152 US granted patents filed between 2015 and 2025, spanning 15 technology areas.

What is Intra-cellular Therapies, Inc.'s Innovation Score?

Intra-cellular Therapies, Inc. has an Innovation Score of 48.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Intra-cellular Therapies, Inc. focus on?

Intra-cellular Therapies, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 128 patents. The company has filed patents in 15 CPC subclasses total.

Is Intra-cellular Therapies, Inc.'s patent filing rate increasing or decreasing?

Intra-cellular Therapies, Inc.'s recent filing velocity is +34% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Intra-cellular Therapies, Inc.'s patents?

Intra-cellular Therapies, Inc.'s patents average 19.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Intra-cellular Therapies, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Intra-cellular's 152 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Intra-cellular ranks #2,558 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.